Objectives: Besides the well-known risk factors for atherosclerosis and cardiovascular disorders, hyperhomocystinemia is a recently defined factor that acts in pathogenesis of atherosclerotic diseases. It also plays role in development of end-stage renal disease. Homocysteine causes endothelial cell damage and proliferation in vascular smooth muscle cells. In this study, we aimed to document the relationship between serum homocyteine levels and postoperative outcomes and occurrence of postoperative adverse events in patients undergoing on-pump cardiac surgery. Materials and Methods: Forty patients undergoing on-pump cardiac surgery were included in the study. Serum homocysteine levels were measured preoperatively. Then, patients were divided into two groups; first group included patients with homocyteine levels below 15 mmol/l and second above. Cross-clamp and cardiopulmonary bypass times, intubation times, intensive care unit and hospital length of stay and occurrence of postoperative adverse events were compared between the two groups. Results: The mean age of the patients was 57.0 ± 2.3 and mean body mass index (BMI) was 26.8 ± 4.1. There were 30 male (75%) and 10 female (25%) patients. The mean preoperative Hcy level was 18.6 ± 10.5 mmol/l. Twenty one patient (52.5%) had Hcy levels below 15 mmol/l and 19 (47.5%) had above 15 mmol/l. The preoperative demographic characteristics of the patients were comparable in two groups. Intubation times, intensive care unit and hospital length of stay were not different between the groups. There was not statistically significant difference between the groups when postoperative renal functions designated by serum creatinine levels and urine output, mortality, occurrence of stroke and mesenteric vascular events were compared. Conclusions: We did not observe any relationship between elevated levels of homocysteine and postoperative stoke, renal failure and other adverse events. We believe that further studies with increased number of patients should be performed.
Introduction
In pathogenesis of vascular atherosclerotic disorders, hyperlipidemia, Diabetes Mellitus, hypertension and smoking are very well-known actors. In addition to the classical risk factors, high levels of serum homocysteine (Hcy) defined as hyperhomocysteinemia (HHS) is a recently identified risk factor (1-7). The incidence of HHC in population is around 5%. The incidence increases up to 13 to 47% in patients with symptomatic atherosclerotic cardiovascular diseases. Patients with HHS usually present with recurrent obstructive arterial or venous thrombosis in age of 30's and 40's or premature coronary artery disease (8) . The mechanism is Hcy-mediated endothelial cellular damage and proliferation in vascular smooth muscle cells (1, 2) .
In last decade, the role of HHS in pathogenesis of end-stage renal disease (ESRD) has also been postulated. Homocysteine is blamed for glomerular cellular damage and fibrosis which are key features in pathogenesis of ESRD (9) .
In this study, we aimed to document the relationship between serum Hcy levels and postoperative outcomes and occurrence of postoperative adverse events (renal failure, cerebrovascular events, mesenteric ischemia and venous thrombosis) in patients undergoing on-pump cardiac surgery. 
Materials and Methods
The study was approved by the Institutional Ethics Committee (11/08/2011; LUT 11/45) and informed consent was obtained from every patient. The study applies the guidelines of The Declaration of Helsinki.
Patients undergoing on-pump cardiac surgery between July 2011 and October 2011 were studied. Patients with preoperative cardiac failure, renal failure and carotid artery stenosis were excluded. Totally, 40 patients were included and prospectively studied.
Anesthesia and Operative Strategy
The patients were administered 5 mg (p.o) diazepam, the night prior to surgery and 5 mg (i.m) diazepam on the day of surgery. For induction of anesthesia ethomidate 0.4 mg/kg, fentanil 1µg/kg, vecuronium bromide 0.1 mg/kg were used. For maintenance 1 MAC sevoflurane together with 50% oxygen (until cardiopulmonary bypass was initiated) and remifentanil 0.25-0.5 µg/kg/min intravenous infusion were given.
Following sternotomy, prior to cannulation 3 mg/kg i.v. heparin was administered and activated clotting time was maintained above 480 seconds. Cardiopulmonary bypass (CPB) was initiated following cannulation. Mean arterial pressure was kept between 40-60 mm Hg with a flow rate of 2.4 L/m2/ min. Moderate hypothermia was employed (28-32 °C). The hematocrit level was kept above 20% throughout the CPB. Following aortic cross-clamp, 15-20 ml/kg cold crystalloid cardioplegia was administered together with cold saline application. After cessation of CPB, heparin was neutralized with protamine (1-1.3 fold dose of heparin). Patients were taken to intensive care unit (ICU) intubated. Hemoglobin levels were kept over 10 g/dl in postoperative period, and 20 ml/kg fresh frozen plasma was administered if excessive drainage was noted.
Postoperative In-hospital Follow-up
Renal functions were monitored by serum creatinine levels and daily urine output. Neurologic status, gastrointestinal functions and lower extremity veins were closely followed with physical examination.
Biochemical Analysis
Serum Hcy levels were measured by high performance liquid chromatography technique and fluorescence detector with Agilent 1100 (Agilent Technologies, Hewlett-Packard-Strasse 8, 76337, Waldbronn, Germany). Homocysteine level above 15 mmol/l was defined as HHC.
Statistical Analysis
Statistical analyses were performed using SPSS software for Windows version 15.0 (Statistical Package for the Social Sciences Inc, Chicago, IL, USA). Continuous variables were expressed as 'mean values ± standard deviation (SD)' and me dian values. Categorical variables were expressed as number and percentages. Demographic characteristics and outcomes of the groups were compared using 'Mann Whitney U test' for continuous variables, and, 'chi-square test' and 'Fisher's exact test' for categorical variables. Statistical significance was set as 'p< 0.05'.
Results
The mean age of the patients was 57.0 ± 2.3 and mean body mass index (BMI) was 26.8 ± 4.1. There were 30 male (75%) and 10 female (25%) patients. The preoperative demographic characteristics and laboratory measurements of the patients are given in Table 1 . The operative procedures performed are given in Table 2. The mean preoperative Hcy level was 18.6 ± 10.5 mmol/l. Twenty one patient (52.5%) had Hcy levels below 15 mmol/l and 19 (47.5%) had above 15 mmol/l. When the age, gender and BMI were compared, there was not statistically significant difference between HHC and non-HHC patients. There was not statistically significant difference between the groups regarding preoperative low-density lipoprotein (LDL) and creatinine levels (Table1). When aortic cross-clamp times and CPB times were compared, there were not statistically significant differences between the groups. Intubation times, ICU stay and hospital length of stay were comparable between the groups (Table 3) .
Postoperative renal functions were evaluated by serum creatinine levels and daily urine output within postoperative first three days. There were not statistically significant differences between the groups regarding these parameters (Table4). Postoperative adverse events were also evaluated. There was no mortality throughout the study period. No mesenteric vascular event was noted. One patient in non-HHC group and three patients in HHC group had cerebrovascular event (p>0.05). There were two cases of postoperative deep venous thrombosis, one in each group (p>0.05) ( Table 5 ).
Table5. Postoperative adverse events HHC:Hyperhomocysteinemia

Discussion
Following establishment of the relation between homocystinuria and atherosclerosis, emboli and premature death, many epidemiologic studies regarding the relation between moderately increased serum levels of Hcy and coronary artery disease, peripheral vascular disease, stroke and venous thromboemboli have been carried out. It was also documented that perioperative morbidity and mortality increases with HHC (10). Long term follow-up studies confirmed the risk increments relalted with HHC (11). In our prospective study, we did not observe any relation with adverse events following on-pump cardiac surgery and HHC.
Nimoniya et al. (9) studied the effects of HHC in population study comprising 1447 patients. In 5 year follow-up 88 patients developed ESRD and there was an inverse correlation between serum Hcy levels and ESRD. Prathapasinghe et al. (12) studied the effects of Hcy on renal ischemia-reperfusion injury in an animal study and documented that injury caused Hcy metabolism derangements and lead to plasma and renal accumulation of Hcy. The resultant HHC caused lipid peroxidation which contributed to ischemia-reperfusion injury and apoptotic as well as necrotic cell death. In the present study, we could not document any relationship between serum Hcy levels and renal functions.
In recent years, accumulated data led the investigators search for the relation with preoperative serum Hcy levels and perioperative morbidity and mortality following cardiac surgery. Ranucci et al. (10) studied 531 patients undergoing cardiac surgery. They formed five groups based on serum Hcy levels. In patients with elevated Hcy levels intubation times and peak serum creatinine levels were higher and mesenteric vascular events and thromboembolic events were more frequent. They also reported increased CPB times in patients with elevated Hcy levels. In coronary bypass patients, perioperative mortality and morbidity increased with increasing Hcy levels. In our study, we failed to document an increase in morbidity or mortality. Intubation times, CPB times, ICU stay and hospital length of stay were not increased.
Elevated Hcy levels cause endothelial dysfunction and decreased nitric oxide release from the endothelium. The affinity of anti-thrombin to endothelial cells decrease. Homocysteine plays as a regulatory agent in coagulation inhibition (13) . It is reported that high levels of Hcy lead to thrombosis tendency (10) . Similarly, CPB leads to excessive release of thrombin, decreased nitric oxide, decreased protein C and tissue factor and finally a tendency to thrombosis (13, 14) . Based on these data, routine use of anticoagulant agents in patients with HHC was speculated.
Despite the conflicting results, moderate to high levels of Hcy was found to be an independent risk factor in ischemic stroke (15) (16) (17) (18) (19) . Yoo et al. (20) revealed that moderately increased level of Hcy was an independent risk factor for cerebral atherosclerosis and ischemic stroke. Brattström et al. (21) studied the correlation between HHS and stroke in 142 patients. Homocyteine levels were increased in stroke patients, patients with carotid artery stenosis and lacunar infarcts and HHC was an independent risk factor. In our study, we observed four cases of stroke throughout the study period, but HHC did not increase stroke rates.
In conclusion, we failed to document the relationship between elevated levels of Hcy and postoperative stoke, renal failure and other adverse events. We believe that further studies with increased number of patients should be performed.
